Skip to main content

Black Diamond Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

BDTX$1.86+7.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Page
PART I - FINANCIAL INFORMATION6
Item 1. Condensed Consolidated Financial Statements (Unaudited)6
Condensed Consolidated Balance Sheets6
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)7
Condensed Consolidated Statements of Cash Flows8
Condensed Consolidated Statements of Stockholders’ Equity9
Notes to Unaudited Condensed Consolidated Financial Statements11
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations25
Item 3. Quantitative and Qualitative Disclosures about Market Risk38
Item 4. Controls and Procedures38
PART II - OTHER INFORMATION39
Item 1. Legal Proceedings39
Item 1A. Risk Factors39
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds47
Item 3. Defaults Upon Senior Securities48
Item 4. Mine Safety Disclosures48
Item 5. Other Information48
Item 6. Exhibits49
SIGNATURES50

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.

From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.